Nature Communications (Sep 2016)
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
- Yunlong Yang,
- Yin Zhang,
- Hideki Iwamoto,
- Kayoko Hosaka,
- Takahiro Seki,
- Patrik Andersson,
- Sharon Lim,
- Carina Fischer,
- Masaki Nakamura,
- Mitsuhiko Abe,
- Renhai Cao,
- Peter Vilhelm Skov,
- Fang Chen,
- Xiaoyun Chen,
- Yongtian Lu,
- Guohui Nie,
- Yihai Cao
Affiliations
- Yunlong Yang
- Key Laboratory of International Collaborations, Second People’s Hospital of Shenzhen, First Affiliated Hospital of Shenzhen University
- Yin Zhang
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Hideki Iwamoto
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Kayoko Hosaka
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Takahiro Seki
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Patrik Andersson
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Sharon Lim
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Carina Fischer
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Masaki Nakamura
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Mitsuhiko Abe
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Renhai Cao
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- Peter Vilhelm Skov
- Section for Aquaculture, The North Sea Research Centre, DTU Aqua, Technical University of Denmark
- Fang Chen
- The First Affiliated Hospital of Zhejiang Chinese Medicine University
- Xiaoyun Chen
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University
- Yongtian Lu
- Key Laboratory of International Collaborations, Second People’s Hospital of Shenzhen, First Affiliated Hospital of Shenzhen University
- Guohui Nie
- Key Laboratory of International Collaborations, Second People’s Hospital of Shenzhen, First Affiliated Hospital of Shenzhen University
- Yihai Cao
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institute
- DOI
- https://doi.org/10.1038/ncomms12680
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 13
Abstract
Anti-VEGF therapy often produces limited beneficial effects in cancer patients. Here, the authors show that discontinuation of anti-VEGF cancer therapy in xenografts-bearing mice increases cancer cells extravasation and intravasation in liver through the host-derived VEGF.
